Literature DB >> 7529215

Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR.

M Salah-Eldin1, G A Peyman, M el-Aswad, B Bandok, M M Bahgat, M R Niesman.   

Abstract

The retinal toxicity of a combination of antineoplastic drugs in free and liposome-encapsulated form was determined in the rabbit eye. Bleomycin sulfate and 5-fluorouridine were evaluated by clinical observation, electroretinogram, and histological study. Forty-five eyes were injected with combinations of various doses of bleomycin and 5-FUR in free and encapsulated form; 10 eyes served as controls. The nontoxic free dose was found to be 3.5 micrograms bleomycin and 150 micrograms 5-FUR. Liposome encapsulation increased the nontoxic dose to 4.7 micrograms bleomycin and 200 micrograms 5-FUR. Four groups of rabbits in which proliferative vitreoretinopathy had been induced were used for the efficacy study; the control group received an injection of PBS; the second group was injected with a combination of 3.5 micrograms bleomycin and 150 micrograms 5-FUR in free form; the third group was injected with the identical doses in liposome-encapsulated form; and the fourth group received encapsulated bleomycin (4.7 micrograms) and 5-FUR (200 micrograms). The dose used in Group 4 was significantly more effective (P < 0.01) in preventing tractional retinal detachment and marginally more effective (P = 0.054) in preventing neovascularization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529215     DOI: 10.1007/bf00919240

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  14 in total

1.  Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.

Authors:  B C Joondeph; G A Peyman; B Khoobehi; B Y Yue
Journal:  Ophthalmic Surg       Date:  1988-04

2.  Evaluation of toxicity of intravitreal antineoplastic drugs.

Authors:  G A Peyman; D Greenberg; G A Fishman; R Fiscella; A Thomas
Journal:  Ophthalmic Surg       Date:  1984-05

3.  Experimental intraocular proliferation and neovascularization.

Authors:  A Ophir; M S Blumenkranz; A J Claflin
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

4.  Ocular toxicity of fluorouracil after vitrectomy.

Authors:  W H Stern; C J Guerin; P A Erickson; G P Lewis; D H Anderson; S K Fisher
Journal:  Am J Ophthalmol       Date:  1983-07       Impact factor: 5.258

5.  The effect of penicillamine on posttraumatic vitreous proliferation.

Authors:  J F Weiss; M Belkin
Journal:  Am J Ophthalmol       Date:  1981-11       Impact factor: 5.258

Review 6.  Proliferative vitreoretinopathy and chemotherapeutic agents.

Authors:  G A Peyman; J Schulman
Journal:  Surv Ophthalmol       Date:  1985 May-Jun       Impact factor: 6.048

7.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation.

Authors:  F Szoka; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

8.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

9.  Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.

Authors:  P Wiedemann; K Lemmen; R Schmiedl; K Heimann
Journal:  Am J Ophthalmol       Date:  1987-07-15       Impact factor: 5.258

10.  Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels.

Authors:  P H Fishman; G A Peyman; T Lesar
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-07       Impact factor: 4.799

View more
  3 in total

1.  Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.

Authors:  Justus G Garweg; Maria Wegmann-Burns; David Goldblum
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-10       Impact factor: 3.117

2.  Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study.

Authors:  C H Kon; R H Asaria; N L Occleston; P T Khaw; G W Aylward
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 3.  Biodegradable intraocular therapies for retinal disorders: progress to date.

Authors:  Noriyuki Kuno; Shinobu Fujii
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.